SERPINE1, serpin family E member 1, 5054

N. diseases: 770; N. variants: 23
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE In conclusion, CAM levels are associated with psoriasis diagnosis and MetS may influence E-selectin and PAI-1 concentrations. 31758356 2020
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Women with MetS had higher values of PAI-1 (36.0 ± 19.1 vs 19.3 ± 14.8 ng/mL, p < .001); in contrast, no differences were observed when compared by hormonal status (20.7 ± 18.10 vs 20.2 ± 17.0 ng/mL, NS). 31023101 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE To compare circulating pigment epithelium derived factor (PEDF) levels in type 2 diabetes patients (T2D) with and without metabolic syndrome (MetS+/-) to healthy controls and assess PEDF association with plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF) as markers of endothelial dysfunction. 30904010 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE A tendency to increase the inflammatory markers IL-6 (p = 0.069) and MCP-1 (p = 0.067) was observed in those patients suffering from MS. An increase in the cardiovascular risk markers PAI-1 (p = 0.007) and triglycerides/HDL cholesterol ratio (p < 0.0001) was also found in the MS group. 30924020 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE We demonstrated that the increase of sICAM-1, sVCAM-1 and PAI-1, together with decrease of omentin-1 led to a proinflammatory imbalance pointing to the presence of subclinical atherosclerosis, and improving CVD risk stratification in non-smoking patients at early stage MetS beyond traditional scores. 31349950 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Elevated PAI-1 antigen levels have been identified as a potential biomarker for coronary artery disease and metabolic syndrome while being modulated by a number of atherosclerotic risk factors. 29494856 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE In addition, PAI-1 values correlated significantly with metabolic syndrome components and carotid IMT. 28822973 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome. 30008151 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE There were significant associations between metabolic syndrome (MetS) and E-selectin and PAI-1. 29400123 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE The elevated level of plasminogen activator inhibitor-1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established. 30002679 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Plasma PAI-1 antigen and activity levels are associated with increased body mass index and with features of the insulin resistance syndrome like obesity and diabetes. 28605281 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Subjects with T2DM plus MetS have elevated PAI-1 levels before clinical manifestations of atherothrombotic disease. 28271069 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Therapeutic disease RGD Pioglitazone in adult rats reverses immediate postnatal overfeeding-induced metabolic, hormonal, and inflammatory alterations. 26084260 2015
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE The current study tried to investigate in parallel the association of PAI-1 activity with the PAI-1 4G/5G polymorphism, with MI, and some components of metabolic syndrome (MetS). 24695040 2014
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE The aim of this study was to analyze the allele and genotype frequencies of these polymorphisms in PAI-1 gene and its association with metabolic syndrome and its components in a sample of Mexican mestizo children. 22459021 2012
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Valsartan reduced plasma PAI-1 levels compared to non-RAS inhibitor in hypertensive patients with MetS, which suggests it may be useful for improving fibrinolytic function. 22451451 2012
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Its predictive ability for MetS and T2DM should not be assessed independently of PAI-1 levels. 21800006 2011
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Plasma IL-6, PAI-1 and TNFα levels were higher in MS. P2X(7)R mRNA and protein, identified in both VAT and SAT, were more abundant in MS than in CTL. 21978920 2011
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE We have investigated the expression of PAI-1, IL-6 and IL-18 in subcutaneous adipose tissue (AT) of subjects with (n = 22) and without (n = 36) MetS. 21842238 2011
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Adipose tissue macrophages: a piece of the PAI of metabolic syndrome. 20371488 2010
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Accordingly, beneficial pleiotropic effects of statins on coronary artery disease may be attributable, in part, to attenuation of overexpression of PAI-1 mediated by the 3'-UTR in syndromes of insulin resistance (such as the metabolic syndrome) and type 2 diabetes. 20299979 2010
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity. 20127289 2010
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE In postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk. 19619703 2009
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Metabolic syndrome-related factors had little influence on PAI-1 levels in White subjects but in African and Indians subjects these variables had a major influence on PAI-1 levels in those with the 5G/5G genotype but not in subjects with the 4G/4G genotype. 17467713 2008
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Circulating plasminogen activator inhibitor-1 levels are elevated at an early stage of impaired glucose tolerance, resulting in diabetes and metabolic syndrome. 18160587 2008